Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Report 2024

The chronic obstructive pulmonary disease (COPD) and asthma devices market size has grown strongly in recent years. It will grow from $42.49 billion in 2023 to $44.95 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The increase observed during the historical period can be ascribed to several factors, including the expanding elderly population, a higher incidence of allergies, more government initiatives, a rise in clinical research and trials, and increasing urbanization.

The chronic obstructive pulmonary disease (COPD) and asthma devices market size is expected to see strong growth in the next few years. It will grow to $57.08 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during the forecast period is expected to stem from the rising prevalence of respiratory diseases, increased cigarette smoking, elevated environmental pollution levels and related breathing issues, greater healthcare spending, and enhanced portability of drug delivery devices. Key trends anticipated for this period include advancements in technology, the integration of smart technology, personalized medicine, the adoption of biologics, and the use of wearable respiratory monitors.

The increasing incidence of respiratory diseases is anticipated to drive the expansion of the chronic obstructive pulmonary disease (COPD) and asthma devices market. Respiratory diseases include various conditions that affect the lungs and respiratory system, such as asthma, COPD, pneumonia, and lung cancer, which impact breathing and overall respiratory function. The rising prevalence of these diseases is linked to factors such as escalating air pollution, climate changes that influence allergens and pathogens, and lifestyle choices such as smoking that impair respiratory health. Devices designed for COPD and asthma are essential for effective management and treatment of these conditions, helping patients achieve better respiratory health and improved overall well-being. For example, as reported by the World Health Organization (WHO) in March 2023, COPD was the third leading cause of death worldwide, accounting for about 3.23 million deaths, with nearly 90% of these fatalities occurring in low- and middle-income countries (LMICs) among individuals under 70 years old. This rising prevalence of respiratory diseases is fueling growth in the COPD and asthma devices market.

Leading companies in the COPD and asthma devices market are concentrating on creating innovative technologies, such as inhalation devices with integrated digital health features for remote monitoring and personalized treatment. Inhalation devices are used to deliver medication directly to the lungs through inhalation. For instance, in May 2022, Alkem Laboratories, an Indian pharmaceutical company, launched the Innohaler, a dry powder inhaler (DPI) designed to improve the lives of people with asthma and COPD. The Innohaler features advanced breath-actuated technology for accurate medication delivery with each inhalation, enhancing dosage precision and minimizing waste. Its ergonomic design makes it easy to use, with a user-friendly interface suitable for patients of all ages. Additionally, its compact and portable design increases convenience for use on the go, supporting better adherence to treatment regimens.

In March 2022, Philip Morris International Inc., a US-based tobacco company, acquired Vectura Group plc. for an undisclosed amount. This acquisition is aimed at utilizing Vectura’s expertise in inhalation technology to advance the development of reduced-risk products (RRPs) and other non-combustible alternatives. Vectura Group plc, a UK-based pharmaceutical company, specializes in inhaled medicines and inhaler devices for treating respiratory diseases such as asthma and COPD.

Major companies operating in the chronic obstructive pulmonary disease (COPD) and asthma devices market are AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, 3M Health Care, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Baxter International Inc., Omron Corporation, Smiths Medical Inc., Recipharm AB, Cipla Ltd., Teleflex Incorporated, Chiesi Farmaceutici SpA, Lincre Holdings Inc., Sunovion Pharmaceuticals Inc., Verona Pharma plc, Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd.

North America was the largest region in the chronic obstructive pulmonary disease (COPD) and asthma devices market in 2023. The regions covered in the chronic obstructive pulmonary disease (COPD) and asthma devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic obstructive pulmonary disease (COPD) and asthma devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Devices for chronic obstructive pulmonary disease (COPD) and asthma are medical tools designed to manage and treat breathing and respiratory issues. These devices assist patients in breathing more efficiently, controlling symptoms, and enhancing their overall quality of life.

Key types of these devices include metered dose inhalers, dry powder inhalers, soft mist inhalers, jet nebulizers, ultrasonic nebulizers, and others. Metered Dose Inhalers are portable devices that administer medication in a precise spray or mist, commonly used for conditions such as COPD and asthma by delivering the medication directly into the lungs. They are small and easy to carry, making them suitable for everyday use. These devices are utilized in various settings such as hospitals, clinics, home care, and research facilities, and cater to different age groups including pediatric, adult, and geriatric patients.

The chronic obstructive pulmonary disease (COPD) and asthma devices market research report is one of a series of new reports that provides chronic obstructive pulmonary disease (COPD) and asthma devices market statistics, including chronic obstructive pulmonary disease (COPD) and asthma devices industry global market size, regional shares, competitors with an chronic obstructive pulmonary disease (COPD) and asthma devices market share, detailed chronic obstructive pulmonary disease (COPD) and asthma devices market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (COPD) and asthma devices industry. This chronic obstructive pulmonary disease (COPD) and asthma devices research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic obstructive pulmonary disease (COPD) and asthma devices market consists of sales of spacer devices, peak flow meters, oxygen therapy equipment, pulse oximeters, and airway clearance devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.